Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 3
2016 9
2017 7
2018 8
2019 9
2020 7
2021 3
2022 4
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Olodaterol for the treatment of chronic obstructive pulmonary disease: a narrative review.
Melani AS. Melani AS. Expert Opin Pharmacother. 2018 Oct;19(14):1603-1611. doi: 10.1080/14656566.2018.1518431. Epub 2018 Oct 12. Expert Opin Pharmacother. 2018. PMID: 30311516 Review.
Inhaled bronchodilators are the key-stone of chronic obstructive pulmonary disease (COPD) management. Olodaterol 5 g, a long-acting beta2-adrenoceptor agonist (LABA) is one such bronchodilator indicated as a once-daily maintenance therapy. ...Co …
Inhaled bronchodilators are the key-stone of chronic obstructive pulmonary disease (COPD) management. Olodate …
Olodaterol for the treatment of chronic obstructive pulmonary disease.
Ramadan WH, Kabbara WK, Abilmona RM. Ramadan WH, et al. Am J Health Syst Pharm. 2016 Aug 1;73(15):1135-43. doi: 10.2146/ajhp150364. Epub 2016 Jun 28. Am J Health Syst Pharm. 2016. PMID: 27354040 Review.
PURPOSE: Published data on the pharmacology, pharmacokinetics, efficacy, and safety of the once-daily, long-acting beta2-agonist (LABA) olodaterol are reviewed. SUMMARY: Olodaterol (Striverdi Respimat, Boehringer Ingelheim), a LABA with high selectivity for beta2-ad …
PURPOSE: Published data on the pharmacology, pharmacokinetics, efficacy, and safety of the once-daily, long-acting beta2-agonist (LABA) o …
Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease.
Ramadan WH, Kabbara WK, El Khoury GM, Al Assir SA. Ramadan WH, et al. Int J Chron Obstruct Pulmon Dis. 2015 Oct 30;10:2347-56. doi: 10.2147/COPD.S88246. eCollection 2015. Int J Chron Obstruct Pulmon Dis. 2015. PMID: 26586940 Free PMC article. Review.
Chronic obstructive pulmonary disease (COPD), a respiratory disease characterized by a progressive decline in lung function, is considered to be a leading cause of morbidity and mortality. ...The combination of olodaterol and tiotropiu …
Chronic obstructive pulmonary disease (COPD), a respiratory disease characterized by a progressive declin …
Tiotropium in chronic obstructive pulmonary disease - a review of clinical development.
Anzueto A, Miravitlles M. Anzueto A, et al. Respir Res. 2020 Jul 29;21(1):199. doi: 10.1186/s12931-020-01407-y. Respir Res. 2020. PMID: 32727455 Free PMC article. Review.
BACKGROUND: Bronchodilators are the mainstay of pharmacological treatment in chronic obstructive pulmonary disease (COPD), and long-acting muscarinic antagonist (LAMA) monotherapy is recommended as initial treatment for Global Initiative for Chronic …
BACKGROUND: Bronchodilators are the mainstay of pharmacological treatment in chronic obstructive pulmonary disease …
Olodaterol: a review of its use in chronic obstructive pulmonary disease.
Deeks ED. Deeks ED. Drugs. 2015 Apr;75(6):665-73. doi: 10.1007/s40265-015-0371-4. Drugs. 2015. PMID: 25773742 Review.
In addition, combined analyses of 48-week trials indicated that olodaterol reduces rescue medication use and may also improve dyspnoea and health-related quality of life, and crossover studies showed improvements in exercise endurance after 6 weeks of treatment with …
In addition, combined analyses of 48-week trials indicated that olodaterol reduces rescue medication use and may also improve dysp …
Tiotropium/Olodaterol: A Review in COPD.
Blair HA. Blair HA. Drugs. 2019 Jun;79(9):997-1008. doi: 10.1007/s40265-019-01133-w. Drugs. 2019. PMID: 31119643 Free PMC article. Review.
Tiotropium/olodaterol (Stiolto() Respimat(); Spiolto() Respimat()) is an inhaled fixed-dose combination of the long-acting muscarinic antagonist tiotropium bromide (hereafter referred to as tiotropium) and the long-acting beta(2)-adrenergic agon …
Tiotropium/olodaterol (Stiolto() Respimat(); Spiolto() Respimat()) is an inhaled fixed-dose combination of the long-acting mus …
Navafenterol for chronic obstructive pulmonary disease therapy.
Antoniu SA, Handra CM, Rascu A, Barbu BA, Chirap Mitulschi I. Antoniu SA, et al. Expert Opin Investig Drugs. 2023 Apr;32(4):283-290. doi: 10.1080/13543784.2023.2199920. Expert Opin Investig Drugs. 2023. PMID: 37017626 Review.
INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is a prevalent disease of the airways in which inhaled bronchodilators can be given as monotherapy or fixed dose combination, in order to better control disease symptoms and to re …
INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is a prevalent disease of the airways in which …
Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol.
Sethi S, Palli SR, Bengtson LGS, Buysman EK, Clark B, Sargent A, Shaikh A, Ferguson GT. Sethi S, et al. J Manag Care Spec Pharm. 2023 Jul;29(7):791-806. doi: 10.18553/jmcp.2023.22373. Epub 2023 May 3. J Manag Care Spec Pharm. 2023. PMID: 37133429 Free PMC article.
BACKGROUND: Clinical practice guidelines recommend dual long-acting muscarinic antagonists (LAMAs)/long-acting beta(2)agonists (LABAs) as maintenance therapy in patients with chronic obstructive pulmonary disease (COPD) and dyspnea or exercise i …
BACKGROUND: Clinical practice guidelines recommend dual long-acting muscarinic antagonists (LAMAs)/long-acting beta(2)agonists (LABAs) as ma …
Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis.
Miravitlles M, Urrutia G, Mathioudakis AG, Ancochea J. Miravitlles M, et al. Respir Res. 2017 Nov 25;18(1):196. doi: 10.1186/s12931-017-0683-x. Respir Res. 2017. PMID: 29178871 Free PMC article. Review.
The new combination of long-acting muscarinic antagonist (LAMA) tiotropium (TIO) and long acting beta-agonists (LABA) olodaterol (OLO) has been introduced as fist line therapy for COPD. ...CONCLUSIONS: Treatment with TIO/OLO provided significant improvements in lung …
The new combination of long-acting muscarinic antagonist (LAMA) tiotropium (TIO) and long acting beta-agonists (LABA) olodaterol …
Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol.
Roskell NS, Anzueto A, Hamilton A, Disse B, Becker K. Roskell NS, et al. Int J Chron Obstruct Pulmon Dis. 2014 Jul 31;9:813-24. doi: 10.2147/COPD.S59673. eCollection 2014. Int J Chron Obstruct Pulmon Dis. 2014. PMID: 25114521 Free PMC article. Review.
PURPOSE: In the absence of head-to-head clinical trials comparing the once-daily, long-acting beta2-agonists olodaterol and indacaterol for the treatment of chronic obstructive pulmonary disease (COPD), an indirect treatment comparison by system …
PURPOSE: In the absence of head-to-head clinical trials comparing the once-daily, long-acting beta2-agonists olodaterol and indacater …
54 results